...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Mediators of inflammation >Activins and Follistatin in Chronic Hepatitis C and Its Treatment with Pegylated-Interferon-αBased Therapy
【24h】

Activins and Follistatin in Chronic Hepatitis C and Its Treatment with Pegylated-Interferon-αBased Therapy

机译：慢性丙型肝炎中的活化素和卵泡抑素及其以聚乙二醇干扰素-α为基础的治疗

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Pegylated-interferon-αbased therapy for the treatment of chronic hepatitis C (CHC) is considered suboptimal as not all patients respond to the treatment and it is associated with several side effects that could lead to dose reduction and/or termination of therapy. The currently used markers to monitor the response to treatment are based on viral kinetics and their performance in the prediction of treatment outcome is moderate and does not combine accuracy and their values have several limitations. Hence, the development of new sensitive and specific predictor markers could provide a useful tool for the clinicians and healthcare providers, especially in the new era of interferon-free therapy, for the classification of patients according to their response to the standard therapy and only subscribing the novel directly acting antiviral drugs to those who are anticipated not to respond to the conventional therapy and/or have absolute contraindications for its use. The importance of activins and follistatin in the regulation of immune system, liver biology, and pathology has recently emerged. This review appraises the up-to-date knowledge regarding the role of activins and follistatin in liver biology and immune system and their role in the pathophysiology of CHC.
机译：基于聚乙二醇干扰素-α的治疗慢性丙型肝炎（CHC）的治疗被认为是次优的，因为并非所有患者都对治疗产生反应，并且它与可能导致剂量减少和/或终止治疗的多种副作用相关。当前使用的用于监测对治疗反应的标记物是基于病毒动力学的，它们在预测治疗结果方面的表现是中等的，并且不具有准确性，其值也有一些局限性。因此，开发新的敏感的和特定的预测指标可以为临床医生和医疗服务提供者提供有用的工具，尤其是在无干扰素治疗的新时代，可以根据患者对标准治疗的反应对患者进行分类，并且仅订阅这种新型直接作用的抗病毒药物适用于那些预期不会对常规疗法产生反应和/或对其使用具有绝对禁忌症的人。最近已经出现了激活素和卵泡抑素在调节免疫系统，肝脏生物学和病理学中的重要性。这篇综述评估了有关激活素和卵泡抑素在肝生物学和免疫系统中的作用及其在CHC病理生理中的作用的最新知识。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号